MedTrace Logo

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2015-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo 0.04 mL twice daily

Subcutaneously injected, 0.04 mL, twice daily

DRUG

Placebo 0.04 mL once daily

Subcutaneously injected, 0.04 mL, once daily

DRUG

Placebo 0.08 mL once daily

Subcutaneously injected, 0.08 mL, once daily

DRUG

B - Exenatide 10 mcg twice daily

Subcutaneously injected, 10 mcg (0.04 mL), twice daily

DRUG

C - Exenatide 10 mcg once daily

Subcutaneously injected, 10 mcg (0.04 mL), once daily

DRUG

Exenatide 20 mcg once daily

Subcutaneously injected, 20 mcg (0.08 mL), once daily

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2004-01-31
Completion
2004-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00085969 on ClinicalTrials.gov